Genetic cluster of fragile X syndrome in a Colombian district

Abstract

Background:

Fragile X syndrome (FXS) is the most common cause of inherited intellectual disabilities and autism. The reported prevalence of the full mutation (FM) gene FMR1 in the general population is 0.2–0.4 per 1000 males and 0.125–0.4 per 1000 females.

Population screening for FMR1 expanded alleles has been performed in newborns and in an adult population. However, it has never been carried out in an entire town.

Ricaurte is a Colombian district with 1186 habitants, with a high prevalence of FXS, which was first described by cytogenetic techniques in 1999.

Methods:

Using a PCR-based approach, screening for FXS was performed on blood spot samples obtained from 926 (502 males and 424 females) inhabitants from Ricaurte, accounting for 78% of total population.

Results:

A high prevalence of carriers of the expanded allele was observed in all FXS mutation categories. Using the Bayesian methods the carrier frequency of FM was 48.2 (95% Credibility Region CR: 36.3–61.5) per 1000 males and 20.5 (95% CR:13.5–28.6) per 1000 females; the frequency of premutation carrier was 14.1 (95% RC: 8.0–21.7) per 1000 males (95% RC: 8.0–21.7 per 1000 males) and 35.9 (95% RC: 26.5–46.2) per 1000 for females (95% RC: 26.5–46.2 per 1000 females), and gray zone carrier was 13.4 (95% RC: 7.4–20.7) per 1000 males (95% RC: 7.4–20.7 per 1000 males) and 42.2 (95% RC: 32.2–53.8) per 1000 for females (95% RC: 32.2–53.8 per 1000 females). Differences in carrier frequencies were observed for premutation and FM alleles between natives and non-natives.

Conclusions:

This study shows that in Ricaurte the carrier frequencies of FMR1 expanded alleles (premutations and FMs) are higher than those reported in the literature, suggesting that Ricaurte constitutes a genetic cluster of FXS.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1

References

  1. 1.

    Hagerman RJ, Hagerman PJ. Fragile X syndrome: diagnosis. In: Hagerman RJ, Hagerman PJ, editors. Treatment and research. 3rd ed. Baltimore: The John Hopkins University Press; 2002.

    Google Scholar 

  2. 2.

    Harris SW, Hessl D, Goodlin-Jones B, Ferranti J, Bacalman S, Barbato I. et al. Autism profiles of males with fragile X syndrome. MacLean WE Jr, Abbeduto L. (eds) Am J Ment Retard. 2008. p. 427–38.

  3. 3.

    Loesch DZ, Huggins RM, Bui QM, Epstein JL, Taylor AK, Hagerman RJ. Effect of the deficits of fragile X mental retardation protein on cognitive status of fragile x males and females assessed by robust pedigree analysis. J Dev Behav Pediatr. 2002;23:416–23.

    Article  PubMed  Google Scholar 

  4. 4.

    Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurol. 2013;12:786–98.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Saldarriaga W, Forero JV, Gonzalez LY, Hagerman R. Síndrome de temblor y ataxia asociado a frágil X (FXTAS): revisión de la literatura. Acta Neurol Colomb. 2015;31:325–34.

    Article  Google Scholar 

  6. 6.

    Wheeler AC, Bailey DB, Berry-Kravis E, Greenberg J, Losh M, Mailick M, et al. Associated features in females with an FMR1 premutation. J Neurodev Disord. 2014;6:18.

    Article  Google Scholar 

  7. 7.

    Roberts JE, Tonnsen BL, McCary LM, Ford AL, Golden RN, Bailey DB. Trajectory and predictors of depression and anxiety disorders in mothers with the FMR1 premutation. Biol Psychiatry. 2016;79:850–7.

    Article  PubMed  Google Scholar 

  8. 8.

    Grigsby J, Cornish K, Hocking D, Kraan C, Olichney JM, Rivera SM, et al. The cognitive neuropsychological phenotype of carriers of the FMR1 premutation. J Neurodev Disord. 2014;6:28.

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Tassone F, Iong KP, Tong T-H, Lo J, Gane LW, Berry-Kravis E, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med. 2012;4:100.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet. 2009;85:503–14.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Tassone F. Advanced technologies for the molecular diagnosis of fragile X syndrome. Expert Rev Mol Diagn. 2015;15:1465–73.

    Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Song F, Barton P, Sleightholme V, Yao G, Fry-Smith A. Screening for fragile X syndrome: a literature review and modeling study HTA Health Technology Assessment NHS R&D HTA Programme Executive Summary Screening for fragile X syndrome. Health Technol Assess (Rockv). 2003;7:1–106.

    CAS  Google Scholar 

  13. 13.

    Hunter J, Rivero-Arias O, Angelov A, Kim E, Fotheringham I, Leal J. Epidemiology of fragile X syndrome: a systematic review and meta-analysis. Am J Med Genet A. 2014;164A:1648–58.

    Article  PubMed  Google Scholar 

  14. 14.

    Meguid N, Abdel-Raouf E, Dardir A, El AM. Prevalence of fragile X syndrome among school-age Egyptian males. World J Pediatr. 2007;3:271–5.

    CAS  Google Scholar 

  15. 15.

    Puusepp H, Kahre T, Sibul H, Soo V, Lind I, Raukas E, et al. Prevalence of the fragile X syndrome among Estonian mentally retarded and the entire children’s population. J Child Neurol. 2008;23:1400–5.

    Article  PubMed  Google Scholar 

  16. 16.

    Turner G, Webb T, Wake S, Robinson H. Prevalence of fragile X syndrome. Am J Med Genet. 1996;64:196–7.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Tzeng C-C, Tsai L-P, Hwu W-L, Lin S-J, Chao M-C, Jong Y-J, et al. Prevalence of the FMR1 mutation in Taiwan assessed by large-scale screening of newborn boys and analysis of DXS548-FRAXAC1 haplotype. Am J Med Genet A. 2005;133A:37–43.

    Article  PubMed  Google Scholar 

  18. 18.

    Chow JC, Chen D-J, Lin C-N, Chiu C-Y, Huang C-B, Chiu P-C, et al. Feasibility of blood spot PCR in large-scale screening of fragile X syndrome in southern Taiwan. J Formos Med Assoc. 2003;102:12–6.

    CAS  PubMed  Google Scholar 

  19. 19.

    Rifé M, Badenas C, Mallolas J, Jiménez L, Cervera R, Maya A, et al. Incidence of Fragile X in 5,000 consecutive newborn males. Genet Test. 2003;7:339–43.

    Article  PubMed  Google Scholar 

  20. 20.

    Saldarriaga W, Tassone F, González-Teshima LY, Forero-Forero JV, Ayala-Zapata S, Hagerman R. Fragile X syndrome. Colomb Med (Cali, Colomb). 2014;45:190–8.

    Google Scholar 

  21. 21.

    Hagerman RJ, Hagerman P. Fragile X-associated tremor/ataxia syndrome—features, mechanisms, and management. Nat Rev Neurol. 2016;12:403–12.

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Payan C, Saldarriaga W, Isaza C, Alzate A. Estudio focoendémico de retardo mental en Ricaurte Valle. In: XI premio Aventis—Academia Nacional de Medicina a la investigaciónmédica. 2000. p. 12–20.

  23. 23.

    Filipovic-Sadic S, Sah S, Chen L, Krosting J, Sekinger E, Zhang W, et al. A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. Clin Chem. 2010;56:399–408.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Tassone F, Pan R, Amiri K, Taylor AK, Hagerman PJ. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn. 2008;10:43–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Maddalena A, Richards CS, Mcginniss MJ, Brothman A, Desnick RJ, Grier RE, et al. Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the standards and guidelines for clinical genetics laboratories of the American College of Medical Genetics.

  26. 26.

    Forster J, O’Hagan A. Kendalls advanced theory of statistics. 2nd ed., vol. 2B (Pb 2015) London: Willey India Exclusive; 2015.

  27. 27.

    Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian data analysis. 3rd ed. Chapman and Hall/CRC; 2013.

  28. 28.

    Sturtz S, Ligges U, Gelman A. R2WinBUGS: A package for running WinBUGS from R. J Stat Softw. 2005;12:1–16.

    Article  Google Scholar 

  29. 29.

    Hagerman PJ. The fragile X prevalence paradox. J Med Genet. 2008;45:498–9.

    Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Fernandez-Carvajal I, Walichiewicz P, Xiaosen X, Pan R, Hagerman PJ, Tassone F. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn. 2009;11:324–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Lopez-Bedoya LM, Ayala-Rodriguez GI. Levantamiento historico corregimiento de Ricaurte municipio de Bolivar. Universidad Tecnologica de Pereira; 1997.

  32. 32.

    Salcedo-Arellano MJ, Lozano R, Tassone F, Hagerman RJ, Saldarriaga W. Alcohol use dependence in fragile X syndrome. Intractable Rare Dis Res. 2016;5:207–13.

    Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Saldarriaga W, Ruiz FA, Tassone F, Hagerman R. Down syndrome and fragile X syndrome in a Colombian woman: case report. J Appl Res Intellect Disabil. 2016;30:970–4.

    Article  PubMed  Google Scholar 

  34. 34.

    Castilla EE, Schuler-Faccini L. From rumors to genetic isolates. Genet Mol Biol. 2014;37(Suppl):186–93.

    Article  PubMed  Google Scholar 

  35. 35.

    Alvarez-Gardeazabal G. “El Divino”. Bogota: Plaza & Janes; 1986.

    Google Scholar 

  36. 36.

    Saldarriaga W, Lein P, González Teshima LY, Isaza C, Rosa L, Polyak A, et al. Phenobarbital use and neurological problems in FMR1 premutation carriers. Neurotoxicology. 2016;53: 141–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Poletta FA, Orioli IM, Castilla EE. Genealogical data in population medical genetics: field guidelines. Genet Mol Biol. 2014;37(Suppl):171–85.

    Article  PubMed  Google Scholar 

  38. 38.

    Crawford DC, Meadows KL, Newman JL, Taft LF, Scott E, Leslie M, et al. Prevalence of the fragile X syndrome in African-Americans. Am J Med Genet. 2002;110:226–33.

    Article  PubMed  Google Scholar 

  39. 39.

    Pesso R, Berkenstadt M, Cuckle H, Gak E, Peleg L, Frydman M, et al. Screening for fragile X syndrome in women of reproductive age. Prenat Diagn. 2000;20:611–4.

    CAS  Article  PubMed  Google Scholar 

  40. 40.

    O’Byrne JJ, Sweeney M, Donnelly DE, Lambert DM, Beattie ED, Gervin CM, et al. Incidence of Fragile X syndrome in Ireland. Am J Med Genet A. 2017;173:678–83.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by UC Davis Seed Grant and by the Universidad del Valle (Colombia) grant 1771. Special thanks to Asuragen, Inc. for providing supplies for this screening study.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Wilmar Saldarriaga or Flora Tassone.

Ethics declarations

Conflict of interest

RJH has received funding from Alcobra, Neuren, Novartis, Roche, and Marinus regarding treatment studies in fragile X syndrome. RJH has also consulted with Zynerba and Ovid regarding treatment studies in fragile X syndrome. FT has received funding from Asuragen, Inc.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Saldarriaga, W., Forero-Forero, J.V., González-Teshima, L.Y. et al. Genetic cluster of fragile X syndrome in a Colombian district. J Hum Genet 63, 509–516 (2018). https://doi.org/10.1038/s10038-017-0407-6

Download citation

Further reading